Fig. 6From: In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosisNanocarrier CCG-222740 does not cause any local toxicity. a Conjunctival vascularity was graded as 0, avascular; 1, normal; 2, hyperaemic; 3, very hyperaemic. b Anterior chamber inflammation was graded as 0, quiet; 1, cells; 2, fibrin; 3, hypopyonBack to article page